Table 1

Ongoing trials of anticoagulation in patients with AF and previous ICH

StudySettingEligibility criteriaInterventionControlPrimary outcome(s)
NASPAF
NCT02998905 		CanadaPrevious ICH
AF, CHADS2 2+		Any NOACAspirin 81 mg/dayICH and ischaemic stroke Mean follow-up 1 year
ASPIRE
NCT03907046 		United StatesPrevious ICH within 14–180 days
AF or atrial flutter, CHA2DS2-VASc 2+		ApixabanAspirin 81 mg/dayAll-cause stroke and death of any cause within 3 years
ENRICH-AF
NCT03950076 		North America, Europe, AsiaPrevious symptomatic intracranial haemorrhage
AF, CHA2DS2-VASc 2+		EdoxabanSingle antiplatelet or no antithrombotic(1) All-cause stroke, (2) Major haemorrhage, median follow-up 2 years
PRESTIGE-AF
NCT03996772 		EuropePrevious ICH within 6 months
AF, CHA2DS2-VASc 2+ (men), 3+ (women)		Any NOACAntiplatelet or no antithrombotic(1) Time to first ischaemic stroke, (2) Time to first ICH, within 3 years
STATICH
NCT03186729 		EuropePrevious ICH
AF or vascular disease with antiplatelet treatment indicated		AF: Any anticoagulant
No AF: Any antiplatelet		AF: No anticoagulant
No AF: No antiplatelet		ICH within 2 years
A3ICH
NCT03243175 		FrancePrevious ICH
AF, CHA2DS2-VASc 2+

  1. Apixaban

  2. LAAO

Antiplatelet or no antithrombotic, no LAAOAll-cause stroke, major cardiovascular events, and major bleeding, within 2 years

  • AF, atrial fibrillation; ICH, intracerebral haemorrhage; LAAO, left atrial appendage occlusion; NOAC, non-vitamin K oral anticoagulant.